Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752613 | 1.00 | MAOA (0.62) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL19683556 | 0.89 | MAOA (0.55) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL19683358 | 0.85 | MAOA (0.52) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL16319037 | 0.79 | MAOA (0.57) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL12279132 | 0.77 | MAOA (0.55) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| Angelicin SCHEMBL8726499 | 0.77 | MAOA (1.00) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| Angelicin SCHEMBL376379 | 0.77 | MAOA (1.00) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| Angelicin SCHEMBL29468230 | 0.77 | MAOA (1.00) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL4429415 | 0.76 | PAX8 (0.48) | MAOAMAOBNFKB1CYP1A1CYP1B1 | |
| SCHEMBL29591293 | 0.76 | MAOA (0.46) | MAOAMAOBNFKB1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617720-B2 | Electroactive composition and electronic device made with the composition | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-12-31 | — | — | US | claimed |
| EP-2516583-A2 | ELECTROACTIVE COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E.I. Du Pont De Nemours And Company (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120187382-A1 | ELECTRONIC DEVICES HAVING LONG LIFETIME | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-07-26 | — | — | US | claimed |
| EP-2379671-A2 | ELECTRONIC DEVICES HAVING LONG LIFETIME | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2011087811-A2 | ELECTROACTIVE COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110147718-A1 | ELECTROACTIVE COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-23 | — | — | US | claimed |
| WO-2010075421-A2 | ELECTRONIC DEVICES HAVING LONG LIFETIME | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-01 | — | — | WO | claimed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | AUBURN UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| CN-114195793-B | Preparation method of chiral amino acid containing C-N-axis nitrogen aryl indole axis | 南京工业大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11539004-B2 | Electroluminescent compound, thermally activated delayed fluorescence material, and application thereof | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20120187383-A1 | ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012021315-A2 | ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| EP-2379671-A2 | ELECTRONIC DEVICES HAVING LONG LIFETIME | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011087811-A2 | ELECTROACTIVE COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110147718-A1 | ELECTROACTIVE COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2010075421-A2 | ELECTRONIC DEVICES HAVING LONG LIFETIME | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2006060082-A1 | TRICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE THEREOF AS CHOLINESTERASE ACTIVITY INHIBITORS | THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120187383-A1 | ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION | CCNL2, ESR1, ESR2 | MAOA 1355/4885MAOB 1188/4885NFKB1 4292/4885 |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | NSFL1C, SOD1, CLTC | MAOA 3686/4885MAOB 3889/4885NFKB1 565/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | MAOA 1416/4885MAOB 1035/4885NFKB1 829/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | MAOA 795/4885MAOB 453/4885NFKB1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.